PremiumCompany AnnouncementsAbeona Therapeutics Advances DEB Treatment with Phase 3b Study Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study Abeona Therapeutics assumed with an Outperform at Oppenheimer PremiumCompany AnnouncementsAbeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success Abeona Therapeutics price target lowered to $20 from $21 at Stifel Abeona Therapeutics price target raised to $27.50 from $25 at Alliance Global Partners PremiumCompany AnnouncementsAbeona Therapeutics Sells Priority Review Voucher for $155M Abeona Therapeutics enters agreement to sell PRV for $155M ABEO Earnings this Week: How Will it Perform? 
